fda warning letters compounded semaglutide tirzepatide 2024 2025 Beyond the Headlines: to GLP-1 Compounders NCL Issues a Second Alert

The year delivered progress across clinical evidence, policy, and changing market dimensions, reinforcing obesity as a chronic disease requiring structured, long-term management

Eden reviewed: monthly pricing, subscription tiers, medication costs, and what's included

Dry mouth affects many people taking semaglutide for weight loss

Retatrutide is the next evolution in GLP-1 weight loss

These medications pose serious health risks due to lack of FDA approval and regulation.

New GLP-1 pill helps patients lose up to 8% of body weight, trial shows Orforglipron led to greater weight loss than semaglutide tablets and could offer more effective oral alternative to jabs A new daily pill could be a more effective GLP-1 tablet for weight loss, according to a clinical trial that may pave the way for an improved non-injection alternative to Wegovy and Mounjaro